Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
Revolution Medicines, Inc.
NantCell, Inc.
Sichuan University
Canadian Cancer Trials Group
Regeneron Pharmaceuticals
Abramson Cancer Center at Penn Medicine
Wake Forest University Health Sciences
West China Hospital
Alliance for Clinical Trials in Oncology
Shenzhen Hornetcorn Bio-technology Company, LTD
University of Alabama at Birmingham
Dana-Farber Cancer Institute
Duke University
University of Southern California
National Cancer Institute (NCI)
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center